Searched for
SALBUTAMOL
Supriya Lifescience to bet on R&D, expansion to grow revenuesSupriya Lifescience, an active pharmaceutical ingredient (API) maker based in Mumbai, aims to double its revenue in the next three years. T...- India bans 14 fixed-dose medicines for likely posing risks to healthThe Indian government has banned 14 types of fixed-dose combination (FDC) medicines due to a lack of therapeutic justification and potentia...
- Govt bans 14 fixed dose combination drugs, cites they may involve risk to peopleThe expert committee said that there is "no therapeutic justification for this FDC (fixed dose combination) and the FDC may involve risk to...
- NPPA revises ceiling prices of 128 formulationsThe National Pharmaceutical Pricing Authority (NPPA) has also fixed the retail price of 12 scheduled formulations under Drugs (Prices Contr...
- Supriya Lifescience lists at 55% premium over issue priceThe Rs 700 crore-IPO by the API manufacturer was sold from December 16 to 20 and was subscribed nearly 72 times, with the IPO getting fully...
- Supriya Lifescience a good bet on healthy growth, valuationsActive pharmaceutical ingredient (API) manufacturer Supriya Lifescience has a niche basket of 38 APIs across therapeutic segments and it ea...
- Supriya Lifescience files DRHP to raise Rs 1,200 crore via IPOThe IPO consists of a fresh issue of shares worth Rs 200 crore and an offer of sale (OFS) of shares worth up to Rs 1,000 crore held by its ...
- Lupin gets EIR from USFDA for Pithampur facility unitLupin's Pithampur facility manufactures dermatological products, dry product inhalers, and metered dose inhalers.
- World Asthma Day: Long-term usage of inhalers can have adverse side effectsNot only prevalent in developed countries, but it is also a major problem in the developing countries.
- Supreme Court backs NPPA on capping drug pricesA bench of Justices Madan B Lokur and RK Agrawal made the observation while ruling on cases related to four formulations of Cipla and one o...
- Wockhardt, Biocon allowed to raise Insulin prices by 18%NPPA has slashed the price of anti-asthma bulk drug used in popular brands such as Cipla's Asthalin, by 18% to Rs 3,633 per kg.
- Cipla receives demand notices from NPPA for Rs 73 crThe company has received further demand notices from the government demanding an amount of Rs 47.70 crore in respect of the drug Salbutamol.
- NPPA slaps Rs 20-cr fine on Cipla for overchargingPharma company Cipla Ltd on Monday said it has received notices, demanding about Rs 20.15 crore, from drug price regulator for allegedly ov...
- Cipla receives notices from NPPA for alleged overchargingDrug firm Cipla said it has received notices from the drug price regulator National Pharmaceutical Pricing Authority allegedly for over-pri...
- Insulin, cancer drugs will cost more soonPrices of various insulin brands and cancer drugs will soon increase while medicines for asthma, meningitis and diphtheria will become chea...
- NPPA cuts prices of three bulk drugs; Cipla, GSK to take a hitNPPA has reduced the price of salbutamol sulphate by almost 6% to Rs 4,478 per kg from Rs 4,748 per kg.
- Government asks Cipla to pay Rs 49.47 cr for overchargingDrug manufacturer Cipla said on Thursday it has received a notice from the government to pay Rs 49.47 crore for "alleged" overcharging on i...
- Government asks Cipla to pay Rs 49.47 cr for overchargingDrug manufacturer Cipla today said it has received a notice from the government to pay Rs 49.47 crore for "alleged" overcharging on its dru...
- Cipla to pay for overcharging drugsThe govt has told Cipla to pay Rs 193.65 crore, inclusive of interest, for overcharging of five drugs.
- Only 33 drugs to stay under price controlIT will be a mixed bag for the pharma industry. Pharma multinationals and domestic drug majors are expected to gain enormously with the che...
Load More
